ARTICLES Monotherapy in adults and elderly persons
|
|
- Shonda Shanon Jenkins
- 6 years ago
- Views:
Transcription
1 ARTICLES Monotherapy in adults and elderly persons Edward Faught, MD Address correspondence and reprint requests to Dr. Edward Faught, Department of Neurology, University of Alabama at Birmingham Epilepsy Center, Civitan International Research Center 312, th Avenue South,Birmingham, AL ABSTRACT Treatment of epilepsy with a single drug has many advantages. Potential benefits of monotherapy vs polytherapy include fewer adverse events and better tolerability, avoidance of drug drug interactions, reduced treatment costs, and improved compliance. Initial treatment should always be monotherapy. Avoidance of pharmacokinetic interactions is a major advantage. Some patients who have achieved seizure control with polytherapy may be candidates for conversion to monotherapy because there is no conclusive evidence that polytherapy provides better seizure control in the majority of patients. Recently published treatment guidelines that take into account the efficacy and tolerability profiles of new and old antiepileptic drugs (AEDs) provide recommendations for drug selection in adults. Elderly patients with epilepsy face unique treatment challenges, which include age-related reductions in liver or kidney function that may alter drug pharmacokinetics. Older persons are more sensitive to CNS side effects; some drugs may exacerbate preexisting problems such as tremor, ataxia, and cognitive difficulty. Many common conditions in the elderly are treated with drugs that are subject to interactions with AEDs. Complex dosing schedules and high drug costs are often barriers to proper care. For all these reasons, monotherapy is especially attractive for the elderly. NEUROLOGY 2007;69(Suppl 3):S3 S9 RATIONALE FOR MONOTHERAPY Adults with epilepsy need complete seizure control with tolerable drug side effects in order to work, drive, and lead a normal social life. Monotherapy is often the best way to achieve these goals. Treatment of epilepsy with a single AED has become the preferred management strategy for most patients over the past three decades. 1 During the 1980s, opinions favoring polytherapy gradually gave way to monotherapy. 2 4 This stems from clinical experience showing that monotherapy offers fewer adverse effects (AEs), lower toxicity, and reduced risk for teratogenicity. Monotherapy also avoids the complex dosing regimens, poorer compliance, and increased treatment costs associated with polytherapy. 1,5,6 Moreover, several studies have shown that polytherapy offers no clear advantage in terms of seizure control and reduced side effects. An early example was a 1983 study of institutionalized, intellectually disabled persons converted from polytherapy to monotherapy, which revealed that 78% remained seizure-free with monotherapy and that many of the patients became more alert. 7 Polytherapeutic treatment plans should be reassessed from time to time to determine if a trial of monotherapy should be undertaken. However, perhaps the single best reason to choose monotherapy is avoidance of pharmacokinetic and pharmacodynamic drug interactions. 1 PHARMACOKINETIC INTERACTIONS BE- TWEEN ANTIEPTILEPTIC DRUGS Careful consideration should be given to the potential interactions resulting from coadministration of AEDs. 8 Most clinically relevant drug interactions among AEDs are pharmacokinetic. These involve interference by one drug with the disposition (metabolism, elimination, absorption) of another, thereby altering the concentration of that drug. 8 In general, the new AEDs have better pharmaco- From the Department of Neurology, University of Alabama School of Medicine, Birmingham, Alabama. This supplement was supported by an educational grant from Novartis Pharmaceuticals Corporation. Disclosure: Dr. Faught has receired honoraria in excess of $ from the sponsor during the course of this study. Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represents the opinions of the authors. These opinions are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology. Copyright 2007 by AAN Enterprises, Inc. S3
2 Table 1 Antiepileptic drug interactions involving the cytochrome P450 system 8 Cytochrome P450 isoenzyme associated with AED metabolism AED Metabolism CYP1A2 CYP2A6 CYP2B CYP2C8 CYP2C9 CYP2C19 CYP2E1 CYP3A4 First-generation AEDs Carbamazepine Cytochrome P450 NA NA? Inhibitor? NA Clobazam Cytochrome P450 Clonazepam Cytochrome P450 Diazepam Cytochrome P450? Ethosuximide Cytochrome P450? Phenobarbital Cytochrome P450?? Phenytoin Cytochrome P450 NA NA Primidone Cytochrome P450?? Valproate Cytochrome P450, glucuronidation (UGT), -oxidation Second-generation AEDs NA Inhibitor NA? Inhibitor? Felbamate Cytochrome P450 NA Inhibitor Gabapentin Not metabolized Lamotrigine Glucuronidation (UGT) Levetiracetam Nonhepatic hydrolysis NA NA NA NA NA NA Oxcarbazepine Glucuronidation of MHD (UGT) and limited Cytochrome P450 metabolism of MHD Inhibitor Tiagabine Cytochrome P450 Topiramate Cytochrome P450, glucuronidation (UGT) NA NA NA NA NA Inhibitor NA NA Vigabatrin Not metabolized NA NA NA NA NA NA NA NA Zonisamide Primarily Cytochrome P450 NA NA NA NA NA NA not affected; no data available; MHD 10,11-dihydro-10-hydroxy-5H-dinenzo b,f azepine-5-carboxamide (the primary pharmacologically active metabolite of ocarbazepine); AED antiepileptic drug; UGT uridine diphosphate glucuronosyl transferase. Reprinted with permission. 8 kinetic profiles and are involved in fewer drug interactions. The most important pathway for drug metabolism among AEDs is the hepatic cytochrome (CYP) P450 enzyme system. 8 Enzyme-inducing drugs such as carbamazepine, phenobarbital, and phenytoin readily enhance the metabolism of other AEDs, thus reducing the therapeutic efficacy of many coadministered drugs (table 1). 8 For example, coadministration of these enzyme-inducing AEDs increases the metabolic rate, reduces the half-life, and therefore lowers the serum concentrations of valproate, lamotrigine, topiramate, zonisamide, and oxcarbazepine. 8 Oxcarbazepine and topiramate inhibit the secondary metabolic enzyme for phenytoin, CYP2C19. At higher serum phenytoin levels, addition of one of these drugs may result in symptoms of phenytoin toxicity. 9 Conversely, discontinuation of one of these enzyme-inducing drugs may cause an increase in serum levels of other AEDs. Selection of drugs with few or no enzyme-inducing or inhibiting effects avoids these complexities and, other factors being equal, is preferable. CANDIDATES FOR MONOTHERAPY There are three situations in which the question of monotherapy may arise: (a) patients embarking on initial treatment of epilepsy; (b) patients with incomplete seizure control on polytherapy; and (c) patients seizure-free on polytherapy. Monotherapy should always be chosen for initial therapy of seizures. FDA-approved agents for initial monotherapy of most seizure types include the older-generation drugs, such as phenytoin, S4 Neurology 69(Suppl 3) December 11, 2007
3 Table 2 Summary of AAN/AES evidence-based guidelines level A or B recommendation for use Drug Newly diagnosed monotherapy partial/mixed seizures Newly diagnosed absence seizures Gabapentin Yes* No Lamotrigine Yes* Yes* Topiramate Yes No Tiagabine No No Oxcarbazepine Yes No Levetiracetam No No Zonisamide No No *Not US FDA-approved for this indication. Reprinted with permission. 11 carbamazepine, and valproate, and the newer agents topiramate and oxcarbazepine. Lamotrigine is approved as a transition to monotherapy; many patients will have been started initially on phenytoin or a benzodiazepine, so this restriction is often moot. However, several randomized controlled trials have supported the use of lamotrigine as initial monotherapy and some single randomized controlled trials support the use of gabapentin and levetiracetam as initial monotherapy. Patients who continue to have seizures on polytherapy may achieve better control by increasing the dose of the single agent in the regimen that appears to have been the most helpful and gradually discontinuing the other drugs. Often an adequate dosage of a single drug is both more effective and better tolerated than inadequate dosages of two or three drugs. Several studies suggest that reducing the number of AEDs may actually provide better seizure control. 10 This maneuver requires caution in outpatients and may be more quickly and safely accomplished in the hospital. Patients who have achieved seizure control with combination therapy are also candidates for conversion to monotherapy, but they require individual consideration. 1 The last-added drug, which presumably was the one temporally associated with complete control, may be a promising choice for monotherapy. This is especially true if either the previous drugs or the current combination of drugs are producing side effects. On the other hand, if a patient is tolerating a polytherapeutic regimen quite well and is seizure-free, continuing this regimen is not an unreasonable choice. Although conversion from polytherapy to monotherapy is a common procedure in clinical practice, patients may be reluctant to convert to a single drug for fear of losing seizure control. The choice should always be made in consultation with the patient. CHOICE OF DRUG FOR MONOTHERAPY: TREATMENT GUIDELINES Three sets of treatment guidelines have been published recently by national 6 and international organizations. All are evidence-based and were derived from literature reviews The guidelines go somewhat beyond FDA-approved indications but rely primarily on randomized controlled trials of each new AED. The American Academy of Neurology (AAN)/ American Epilepsy Society (AES) guidelines support the use of established older drugs for monotherapy of new-onset seizures and the use of several of the newer agents (table 2). 11 For adults with refractory partial epilepsy, the AAN and AES recommend oxcarbazepine and topiramate as monotherapy and gabapentin, lamotrigine, tiagabine, topiramate, oxcarbazepine, levetiracetam, or zonisamide as add-on therapy. 11 Topiramate is recommended for the treatment of refractory generalized tonic clonic seizures in adults. 11 Both topiramate and lamotrigine are recommended to treat drop attacks associated with the Lennox Gastaut syndrome. 11 Guidelines for the use of new AEDs published in the United Kingdom by the National Institute for Clinical Excellence (NICE) were developed from examination of the results of randomized controlled trials (RCTs) and systematic reviews comparing new AEDs with older drugs, placebo, or other new agents. 12 In general, these guidelines are more conservative than the AAN guidelines. The NICE guidelines recommend use of a new AED for the following reasons: an older drug would not be beneficial; the older drug is contraindicated because of potential interactions with other agents; there is evidence of a previous nega- Neurology 69(Suppl 3) December 11, 2007 S5
4 tive experience or lack of tolerability; or the patient is a woman of childbearing age. 12,14 The International League Against Epilepsy (ILAE) guidelines are based on a structured review of the literature in which quality of clinical trial evidence was used to determine the strength of the level of recommendation. 13 These guidelines focus on agent efficacy as initial monotherapy for newly diagnosed or untreated epilepsy. 13 For the treatment of adults with generalized tonic clonic seizures, no AED reached the highest level of evidence, but carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, topiramate, and valproate are considered possibly efficacious as monotherapy for selected situations, based on results observed in RCTs. 13 In adults with newly diagnosed partial-onset seizures, it was considered established that carbamazepine and phenytoin are efficacious as initial monotherapy, while valproate was considered probably efficacious, and gabapentin, lamotrigine, oxcarbazepine, phenobarbital, topiramate, and vigabatrin were deemed possibly efficacious. 13 Recommendations for the treatment of elderly adults with partial-onset seizures included carbamazepine, gabapentin, and lamotrigine, all of which achieved the highest level of evidence for effectiveness. 13 CHOICE OF DRUG FOR MONOTHERAPY: SIDE EFFECTS Because there are several effective agents, the choice of a drug often depends on the assessment of side effects in each patient. All commonly used AEDs may cause CNS dysfunction, including cognitive impairment. 15 In a cross-sectional survey of over 300 adults with treated epilepsy, more than 60% reported subjective complaints regarded as drug side effects. CNS-related effects (e.g., fatigue and dizziness) and cognitive complaints (e.g., memory problems, concentration difficulties) were reported most often (table 3). 16 The results of this survey illustrate that many patients experience side effects and attribute them to their AED. Although side effects may not be obvious to clinicians, the majority of patients on AED therapy are bothered by them despite good seizure control. In addition to the common dose-related CNS side effects, AEDs may have clinically relevant metabolic side effects. Long-term use of AEDs may lead to altered bone metabolism, resulting in decreased bone mineral density and increased risk for fractures. 17 Valproate, carbamazepine, gabapentin, and pregabalin may be associated with weight gain, which might be of sufficient degree to affect long-term health risks. 17 Carbamazepine, phenobarbital, and phenytoin are associated with variable increases in total serum cholesterol, triglycerides, high-density lipoproteins, and lowdensity lipoprotein, athough the clinical significance of these effects is unknown. 18 CHALLENGES IN TREATING EPILEPSY IN EL- DERLY ADULTS There are special reasons for favoring monotherapy in older patients. Epilepsy and single seizures are surprisingly common in the elderly, often caused by cerebrovascular disease or other focal pathology. 19,20 The incidence of epilepsy surges after the age of 60, with one study reporting 25% of all new cases occurring in this age group (figure). 19 The treatment of epilepsy in elderly patients presents unique challenges. 21 Injuries caused by seizures may be more severe and postictal confusion may be more prolonged. Although the impact of seizures on employment may be less for retired persons, loss of a driver s license is a serious blow to independence at any age. There are age-related changes in pharmacokinetic parameters, including protein binding, distribution, and elimination, that can lead to reduced drug clearance, increased receptor sensitivity, and therefore to increased risk for dose-related side effects. 22 Perhaps most importantly, older patients often take multiple medications, greatly increasing the chance of pharmacokinetic and pharmacodynamic drug interactions (table 4). 19 No matter which drug is chosen, it should be initiated at the lowest possible dose and titrated slowly. 19 A good rule of thumb is to start with about half the recommended dose for younger adults and to aim for an initial target dose of half to two-thirds of the optimal dose for younger adults. It is important not to make preexisting problems worse by a poor choice of drug. Phenytoin is not a good choice for those with poor balance, valproate is not a good choice for those with essential tremor, and sedative drugs are not good choices for somnolent or demented patients. 11,17 Older AEDs present the added concern of hepatic enzyme induction, which can increase the risk for drug interactions. There are only a few wellcontrolled trials of AEDs in elderly patients, although several of the new drugs have characteristics that may be favorable for this population (table 5). 19 Other drugs may be appropriate for selected patients, especially if used in conservative doses. REASONS FOR POLYTHERAPY Monotherapy results in seizure control in the majority of pa- S6 Neurology 69(Suppl 3) December 11, 2007
5 Table 3 Subjective reported side effects Area and type of side effect * Complaints (%) General CNS 68.2 (overall CNS complaints) Fatigue 20.3 Tiredness 18.8 General slowing 12.1 Headache 8.9 Dizziness 8.1 Motor problems 31.5 (overall motor complaints) Tremor 13.3 Ataxia 13.0 Falling 5.2 Gastrointestinal complaints 33.2 (overall gastrointestinal complaints) Weight gain 12.4 Defecation problems 8.4 Loss of appetite 5.2 Nausea 2.9 Diarrhea 2.3 Weight loss 2.0 Cognition 61.8 (overall cognitive complaints) Memory problems 21.4 Concentration difficulties 16.1 Speech problems 8.7 Language difficulties 7.8 Visual 7.5 (overall visual complaints) Double vision 7.5 Mood and behavior 22.3 (overall mood/behavior complaints) Agitation/irritability 14.8 Depression 7.5 Cosmetic 20.4 (overall cosmetic complaints) Hair loss 7.2 Gum problems 7.8 Skin complaints 5.4 Sleep problems 8.7 (overall sleep complaints) Insomnia 8.7 *One patient may be reporting several side effects. Summary of both moderate and severe complaints. Reprinted with permission. 16 Figure 1 Incidence of epileptic seizures by age tients but sometimes fails because of lack of efficacy, dose-related side effects, or an idiosyncratic side effect. In patients in whom two or three drugs have failed as monotherapy, a polytherapeutic regimen may be necessary (table 6). 23 Fortunately, polytherapeutic regimens are easier to administer now because of the paucity of drug interactions among many of the newer drugs. Although the concept of selecting two or more drugs with different and possibly complementary mechanisms of action is scientifically appealing, the superior- band. Reprinted with permission. 19 Neurology 69(Suppl 3) December 11, 2007 S7
6 Table 4 Interactions of antiepileptic drugs with medications frequently coadministered in elderly adults Comedication CBZ PHT VPA PB PMD OXC TPM TGB LTG GBP LEV VGB Warfarin??? Digoxin?? Neuroleptics?? -? Antacids?? -?? - - Antibiotics???? CBZ carbamazepine; PHT phenytoin; VPA valproate; PB phenobarbital; PMD primidone; OXC oxcarbazapine; TPM topiramate; TGB tiagabine; LTG lamotrigine; GBP gabapentin; LEV levetiracetam; VGB vigabatrin. Reprinted with permission. 19 Table 5 Profiles of some antiepileptic drugs suitable for use in elderly adults AED Advantages Disadvantages Doses/day Gabapentin No drug interactions, excellent tolerability, rapid titration Possibly less potent, dose dependent on renal function 2 3 Levetiracetam Effective, no drug interactions, good tolerability, rapid titration, effective at low doses (1,000 mg) Behavioral disturbances, somnolence, limited monotherapy experience 2 Lamotrigine Effective, very favorable cognitive profile; approved for monotherapy Slow titration, allergic reactions, some drug interactions, insomnia 2 Oxcarbazepine Effective, fewer drug interactions and AEs than carbamazepine; approved for monotherapy Hyponatremia, dizziness 2 Topiramate Effective, renal and hepatic excretion, welltolerated in low doses (100 mg); approved for monotherapy Cognitive impairment, weight loss, titration within 3 4 weeks 2 Valproate Loadable, parenteral, broad- spectrum, no enzyme induction Enzyme inhibitor, weight gain, tremor, occasional encephalopathy in elderly 1 AED antiepileptic drug. Adapted with permission. 19 Table 6 Recommended treatment strategy when first-line monotherapy fails in patients with epilepsy Reason for failure Lack of seizure control but no toxicity Lack of seizure control at the maximal dose tolerated Unacceptable dose-related adverse effects at the lowest possible maintenance dose Unacceptable idiosyncratic reactions Action Increase the dose of the first-line drug Lower the dose of first-line drug and add another drug; evaluate effectiveness of combination before withdrawing the first-line drug Rapid substitution Immediate substitution Reprinted with permission. 23 ity of this approach has never been convincingly demonstrated. SUMMARY Most of the advantages of monotherapy lower cost, simpler dosing schedules, less possibility of additive toxicities and drug interactions are readily apparent and are especially important for elderly adults. Overuse of polytherapy regimens stems primarily from the mistaken belief that efficacy is better with more drugs. For most patients, both tolerability and seizure control are superior with a sufficient dosage of a single drug rather than an insufficient dosage of several. If polytherapy is chosen, care must be taken to ensure that tolerability is not compromised and that combinations not subject to undesirable drug interactions are used. REFERENCES 1. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord 2003;5: Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia 1981; 22: Lesser RP, Pippenger CE, Lüders H, Dinner DS. Highdose monotherapy in treatment of intractable seizures. Neurology 1984;34: S8 Neurology 69(Suppl 3) December 11, 2007
7 4. Wilder BJ. Treatment considerations in anticonvulsant monotherapy. Epilepsia 1987;28(suppl 2):S Schmidt D. Monotherapy versus polytherapy in epilepsy. A reappraisal. CNS Drugs 1995;3: Kanner AM, Balabanov AJ. The use of monotherapy in patients with epilepsy: an appraisal of the new antiepileptic drugs. Curr Neurol Neurosci Rep 2005;5: Bennett HS, Dunlop T, Ziring P. Reduction of polypharmacy for epilepsy in an institution for the retarded. Dev Med Child Neurol 1983;25: Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43: LaRoche SM. A new look at the second-generation antiepileptic drugs. A decade of experience. Neurologist 2007;13: Shorvon SD, Chadwick D, Galbraith AW, Reynolds EH. One drug for epilepsy. BMJ 1978;1: French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62: National Institute for Clinical Excellence. The epilepsies: diagnosis and management of the epilepsies in adults in primary and secondary care. 2004a. Available at: CG020adult. Accessed November 15, Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47: Beghi E, Annagers JF. Pregnancy registries in epilepsy. Epilepsia 2001;42: Aldenkamp AP, De Krom M, Reijs R. Newer epileptic drugs and cognitive issues. Epilepsia 2003;44: Carpay JA, Aldenkamp AP, van Donselaar CA. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 2005; 14: Sheth RD. Metabolic concerns associated with antiepileptic medications. Neurology 2004;63(suppl 4):S Nikolaos T, Stylianos G, Chryssoula N, et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 2004;10:MT Pohlmann-Eden B. Issues when treating epilepsy in the elderly. Acta Neurol Scand 2005(suppl);181: Hauser WA. Seizure disorders: the changes with age. Epilepsia 1992;33(suppl 4):S Faught E. Epidemiology and drug treatment of epilepsy in elderly people. Drugs Aging 1999;15: Bourdet SV, Gidal BE, Alldredge BK. Pharmacologic management of epilepsy in the elderly. J Am Pharm Assoc 2001;41: Deckers CL. Place of polytherapy in the early treatment of epilepsy. CNS Drugs 2002;16: Neurology 69(Suppl 3) December 11, 2007 S9
Difficult to treat childhood epilepsy: Lessons from clinical case scenario
Difficult to treat childhood epilepsy: Lessons from clinical case scenario Surachai Likasitwattanakul, M.D. Department of Pediatrics Faculty of Medicine, Siriraj Hospital Natural history of Epilepsy Untreated
More informationAED Treatment Approaches. David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology
AED Treatment Approaches David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology Audience Response Keypads Please utilize the keypad at your table to answer questions throughout
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More informationDisclosure. Learning Objectives
Linda D. Leary, M.D. Associate Clinical Professor of Pediatrics & Neurology South Texas Comprehensive Epilepsy Center UT Health Science Center San Antonio Disclosure Linda D. Leary, M.D. discloses the
More information7/31/09. New AEDs. AEDs. Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital. 1 st genera*on AEDs
Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital New AEDs AEDs NEW OLD Pregabalin Pregabalin 1 st genera*on AEDs Phenytoin Carbamazepine Valproate Phenobarbital
More informationTherapeutic strategies in the choice of antiepileptic drugs
Acta neurol. belg., 2002, 102, 6-10 Original articles Therapeutic strategies in the choice of antiepileptic drugs V. DE BORCHGRAVE, V. DELVAUX, M. DE TOURCHANINOFF, J.M. DUBRU, S. GHARIANI, Th. GRISAR,
More informationPharmacological Treatment of Non-Lesional Epilepsy December 8, 2013
Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013 Michael Privitera, MD Professor of Neurology University of Cincinnati, Neuroscience Institute American Epilepsy Society Annual Meeting
More informationUpdate in Clinical Guidelines in Epilepsy
Why We Need Clinical Guidelines? Clinician needs advice! Update in Clinical Guidelines in Epilepsy Charcrin Nabangchang, M.D. Phramongkutklao College of Medicine Tiamkao S, Neurology Asia2013 Why We Need
More informationEpilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society
Epilepsy 101 Overview of Treatment Kathryn A. O Hara RN American Epilepsy Society Objectives Describe the main treatment options for epilepsy Identify factors essential in the selection of appropriate
More informationEpilepsy and EEG in Clinical Practice
Mayo School of Professional Development Epilepsy and EEG in Clinical Practice November 10-12, 2016 Hard Rock Hotel at Universal Orlando Orlando, FL Course Directors Jeffrey Britton, MD and William Tatum,
More informationErnie Somerville Prince of Wales Hospital EPILEPSY
Ernie Somerville Prince of Wales Hospital EPILEPSY Overview Classification New and old anti-epileptic drugs (AEDs) Neuropsychiatric side-effects Limbic encephalitis Non-drug therapies Therapeutic wishlist
More informationNew antiepileptic drugs
Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-Onset Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of
More informationEpilepsia, 45(5): , 2004 Blackwell Publishing, Inc. C 2004 International League Against Epilepsy. C 2004 AAN Enterprises, Inc.
Epilepsia, 45(5):410 423, 2004 Blackwell Publishing, Inc. C 2004 International League Against Epilepsy C 2004 AAN Enterprises, Inc. Efficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment
More informationChildren Are Not Just Small Adults Choosing AEDs in Children
Children Are Not Just Small Adults Choosing AEDs in Children Natrujee Wiwattanadittakun, MD Neurology division, Department of Pediatrics, Chiang Mai University Hospital, Chiang Mai University 20 th July,
More informationNew AEDs in Uncontrolled seizures
New AEDs in Uncontrolled seizures Uncontrolled seizures/epilepsy Intractable epilepsy, Refractory epilepsy, Pharmacoresistant epilepsy Dr. Suthida Yenjun Traditionally, referred to therapeutic failure
More informationEPILEPSY: SPECTRUM OF CHANGE WITH AGE. Gail D. Anderson, Ph.D.
EPILEPSY: SPECTRUM OF CHANGE WITH AGE Gail D. Anderson, Ph.D. Incidence: 0.5% - 1.0% of U.S. population Peak incidence of onset: first 2 years of life, ages 5-7 years, early puberty and elderly. 125,000
More informationCLINICIAN INTERVIEW AS i M: When you examine a clinical trial in new- onset epilepsy, how relevant are the results to your daily clinical practice?
FROM CLINICAL TRIALS TO CLINICAL PRACTICE: TRANSLATING EPILEPSY RESEARCH INTO PATIENT CARE Interview with Jacqueline A. French, MD Dr Jacqueline A. French is a Professor in the Department of Neurology
More informationEpilepsy T.I.A. Cataplexy. Nonepileptic seizure. syncope. Dystonia. Epilepsy & other attack disorders Overview
: Clinical presentation and management Markus Reuber Professor of Clinical Neurology Academic Neurology Unit University of Sheffield, Royal Hallamshire Hospital. Is it epilepsy? Overview Common attack
More informationAnticonvulsants Antiseizure
Anticonvulsants Antiseizure Seizure disorders Head trauma Stroke Drugs (overdose, withdrawal) Brain tumor Encephalitis/ Meningitis High fever Hypoglycemia Hypocalcemia Hypoxia genetic factors Epileptic
More informationUpdated advice for nurses who care for patients with epilepsy
NICE BULLETIN Updated advice for nurses who care for patients with epilepsy NICE provided the content for this booklet which is independent of any company or product advertised NICE BULLETIN Updated advice
More informationPrescribing and Monitoring Anti-Epileptic Drugs
Prescribing and Monitoring Anti-Epileptic Drugs Mark Granner, MD Clinical Professor and Vice Chair for Clinical Programs Director, Iowa Comprehensive Epilepsy Program Department of Neurology University
More information8/30/10. How to use Antiepileptic drugs properly. 3nd generation AEDs. Introduction. Introduction. Introduction. AEDs. Dr.Yotin Chinvarun M.D., Ph.D.
Introduction How to use Antiepileptic drugs properly Modern treatment of seizures started in 1850 with the introduction of bromides, based on the theory that epilepsy was caused by an excessive sex drive
More informationNewer AEDs compared to LVT as adjunctive treatments for uncontrolled focal epilepsy. Dr. Yotin Chinvarun. M.D. Ph.D.
Newer AEDs compared to LVT as adjunctive treatments for uncontrolled focal epilepsy Dr. Yotin Chinvarun. M.D. Ph.D. Chronology of antiepileptic drug introduction over the past 150 years 20 15 10 Perampanel
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-Resistant Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the
More informationTailoring therapy to optimize care for Epilepsy. Dr Tim Wehner National Hospital for Neurology and Neurosurgery London, UK For discussion only
Tailoring therapy to optimize care for Epilepsy Dr Tim Wehner National Hospital for Neurology and Neurosurgery London, UK For discussion only Disclosures Session (travel expenses) sponsored by Pfizer Premature
More informationThe Epilepsy Prescriber s Guide to Antiepileptic Drugs
The Epilepsy Prescriber s Guide to Antiepileptic Drugs The Epilepsy Prescriber s Guide to Antiepileptic Drugs Philip N. Patsalos FRCPath, PhD Professor of Clinical Pharmacology and Consultant Clinical
More informationEpilepsy is a very individualized
... PRESENTATION... Treatment of Epilepsy in 3 Specialized Populations Based on a presentation by Ilo E. Leppik, MD Presentation Summary When discussing the treatment of epilepsy, targeted populations
More informationNeuromuscular Disease(2) Epilepsy. Department of Pediatrics Soochow University Affiliated Children s Hospital
Neuromuscular Disease(2) Epilepsy Department of Pediatrics Soochow University Affiliated Children s Hospital Seizures (p130) Main contents: 1) Emphasize the clinical features of epileptic seizure and epilepsy.
More informationAN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS
Volume 24, Issue 1 October 2008 AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS Jason Richey, Pharm.D. Candidate Epilepsy is a neurological disorder characterized by sudden
More informationTITLE: Pharmacological Treatments in Patients with Epilepsy: Guidelines
TITLE: Pharmacological Treatments in Patients with Epilepsy: Guidelines DATE: 01 April 2011 RESEARCH QUESTION What are the evidence-based guidelines for pharmacological treatments in patients with epilepsy?
More informationEpilepsy 7/28/09! Definitions. Classification of epilepsy. Epidemiology of Seizures and Epilepsy. International classification of epilepsies
Definitions Epilepsy Dr.Yotin Chinvarun M.D., Ph.D. Seizure: the clinical manifestation of an abnormal and excessive excitation of a population of cortical neurons Epilepsy: a tendency toward recurrent
More informationModified release drug delivery system for antiepileptic drug (Formulation development and evaluation).
TITLE OF THE THESIS / RESEARCH: Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). INTRODUCTION: Epilepsy is a common chronic neurological disorder characterized
More informationEfficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy
Special Article Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee
More informationTreatment of epilepsy in adults
Treatment of epilepsy in adults Review 33 Treatment of epilepsy in adults S B Gunatilake 1, A Arasalingam 2 Sri Lanka Journal of Neurology, 2012, 1, 33-38 Case vignettes 1. A 60-year old patient with long
More informationEpilepsy Medications: The Basics
Epilepsy Medications: The Basics B R I A N A P P A V U, M D C L I N I C A L A S S I S T A N T P R O F E S S O R, D E P A R T M E N T O F C H I L D H E A L T H A N D N E U R O L O G Y, U N I V E R S I T
More informationSeizure medications An overview
Seizure medications An overview Andrew Zillgitt, DO Staff Neurologist Comprehensive Epilepsy Center Department of Neurology Henry Ford Hospital None Disclosures Objectives A lot to review!!!!! Look at
More informationEpilepsy management What, when and how?
Epilepsy management What, when and how? J Helen Cross UCL-Institute of Child Health, Great Ormond Street Hospital for Children, London, & National Centre for Young People with Epilepsy, Lingfield, UK What
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationMONOTHERAPY OR POLYTHERAPY FOR CHILDHOOD EPILEPSIES?
MONOTHERAPY OR POLYTHERAPY FOR CHILDHOOD EPILEPSIES? Oluwaseun Egunsola 1, Helen M Sammons 1 and William P Whitehouse 2,3 1Academic Division of Child Health, University of Nottingham, Derbyshire Children
More informationManagement of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse
Management of Epilepsy in Primary Care and the Community Carrie Burke, Epilepsy Specialist Nurse Epilepsy & Seizures Epilepsy is a common neurological disorder characterised by recurring seizures (NICE,
More informationSODIUM CHANNEL BLOCKERS IN THE 21 ST CENTURY. Professor Martin J Brodie University of Glasgow Glasgow, Scotland
IN THE 21 ST CENTURY Professor Martin J Brodie University of Glasgow Glasgow, Scotland Eisai SODIUM CHANNEL BLOCKERS Declaration of interests UCB Pharma GlaxoSmithKline Lundbeck Takeda Advisory board,
More informationANTIEPILEPTIC Medicines
ANTIEPILEPTIC Medicines Treatment with antiepileptic medicines currently enables over 70% of people with epilepsy to live free of seizures. In the last few days years several new medicines have become
More informationReview of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP
Review of Anticonvulsant Medications: Traditional and Alternative Uses Andrea Michel, PharmD, CACP Objectives Review epidemiology of epilepsy Classify types of seizures Discuss non-pharmacologic and pharmacologic
More informationWHY CHILDREN ARE DIFFERENT FROM ADULTS
XXASIM May p159-165 5/14/01 9:23 AM Page 159 NEW PHARMACOLOGICAL TREATMENTS FOR PEDIATRIC EPILEPSY Blaise F.D. Bourgeois, MD KEY POINTS Antiepileptic drugs (AEDs) are tailored to pediatric epilepsy seizure
More informationSlide 1. Slide 2. Slide 3. Objectives. Why should we care about the elderly? Antiseizure Drugs in Elderly Patients
Slide 1 Antiseizure Drugs in Elderly Patients Angela Birnbaum, Ph.D. Professor Epilepsy Research and Education Program Center for Clinical and Cognitive Neuropharmacology College of Pharmacy University
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationValproate Case 3: Formulations Jose de Leon, MD
Valproate Case 3: Formulations 2-12-16 Jose de Leon, MD 3.Valproate Case 3 Described in J Clin Psychiatry 2004;65:724-5 http://www.ncbi.nlm.nih.gov/pubmed/15163266 Pharmacological explanation provided
More informationXournals. The Use Antiepileptic Drug (AED) during Pregnancy. Surya Kiran Sharma 1. Abstract: Authors:
ISSN UA Volume 01 Issue 01 June-2018 The Use Antiepileptic Drug (AED) during Pregnancy Surya Kiran Sharma 1 Available online at: www.xournals.com Received 13 th December 2017 Revised 15 th February 2018
More informationIntroduction to seizures and epilepsy
Introduction to seizures and epilepsy Selim R. Benbadis, M.D. Professor Departments of Neurology & Neurosurgery Director, Comprehensive Epilepsy Program Symptomatic seizures Head injury (trauma) Stroke
More informationTIAGABINE. THERAPEUTICS Brands Gabitril see index for additional brand names. Generic? Yes
TIAGABINE THERAPEUTICS Brands Gabitril see index for additional brand names Generic? Yes Class Anticonvulsant; selective GABA reuptake inhibitor (SGRI) Commonly Prescribed for (bold for FDA approved) Partial
More informationNew drugs necessity for therapeutic drug monitoring
New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range
More informationZONISAMIDE THERAPEUTICS. Brands * Zonegran. Generic? Not in US. If It Doesn t Work * Class Antiepileptic drug (AED), structurally a sulfonamide
Z:/3-PAGINATION/SBT/2-PROOFS/NWMS/9780521136723C111//9780521136723C111.3D 376 [376 380] ZONISAMIDE Brands Zonegran Generic? Not in US THERAPEUTICS Class Antiepileptic drug (AED), structurally a sulfonamide
More informationDisclosures. AED Options. Epilepsy Pharmacotherapy: Treatment Considerations with Older AEDs
Epilepsy Pharmacotherapy: Treatment Considerations with Older AEDs BARRY E. GIDAL, PHARMD PROFESSOR SCHOOL OF PHARMACY & DEPT. OF NEUROLOGY Disclosures Speaking honoraria: UCB, Eisai, Sunovion Consultant:
More informationThe primary goal of antiepileptic drug
THE ROLE OF THERAPEUTIC DRUG MONITORING IN PATIENT CARE * Page B. Pennell, MD ABSTRACT The dose-response relationship for antiepileptic drugs (AEDs) varies enormously between and within individual patients.
More informationMONOTHERAPY IS PREferred
Monotherapy in Epilepsy Role of the Newer Antiepileptic Drugs Blanca Vazquez, MD NEUROLOGICAL REVIEW Background: Monotherapy is the goal for pharmacological treatment of epilepsy. Well-controlled trials
More informationEfficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy
Special Article CME Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee
More informationAmerican Epilepsy Society Guidelines
Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy Report of the American Epilepsy Society and the Guideline Development, Dissemination,
More informationLevetiracetam in patients with generalised epilepsy and myoclonic seizures: An open label study
Seizure (2006) 15, 214 218 www.elsevier.com/locate/yseiz CASE REPORT Levetiracetam in patients with generalised epilepsy and myoclonic seizures: An open label study Angelo Labate a,b, Eleonora Colosimo
More informationValproate Case 1: Pharmacokinetics Jose de Leon, MD
Valproate Case 1: Pharmacokinetics 2-12-16 Jose de Leon, MD 1. Valproate Case 1 J Clin Psychopharmacology 2009;29:509-11 http://www.ncbi.nlm.nih.gov/pubmed/19745660 Educational Objectives At the conclusion
More informationAPPENDIX S. Removed sections from original guideline. 1.1 Pharmacological treatment Introduction
00 0 APPENDIX S Removed sections from original guideline. Pharmacological treatment.. Introduction The evidence base for the newer AEDs (gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine,
More information11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova
EPILEPSY UPDATE Dr.Ram Sankaraneni Disclosures Speaker bureau LivaNova 1 Outline New onset Seizure Investigations in patients with epilepsy Medical management of epilepsy Non Pharmacological options in
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationORIGINAL CONTRIBUTION. Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy
ORIGINAL CONTRIBUTION Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy Hiba Arif, MD; Richard Buchsbaum; Joanna Pierro, BA; Michael Whalen, BA; Jessica Sims, MD; Stanley
More informationTRANSPARENCY COMMITTEE OPINION. 19 July 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated
More informationNew Medicines Profile
New Medicines Profile February 2010 Issue No. 10/02 Eslicarbazepine Concise evaluated information to support the managed entry of new medicines in the NHS Brand Name, (Manufacturer): Zebinix (Eisai Limited)
More informationMedications for Epilepsy What I Need to Know
Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for
More informationEvidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy
Seizure (2006) 15, 112 116 www.elsevier.com/locate/yseiz Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy Luigi M. Specchio a,e, *, Giovanni Boero b,e,
More informationThe Selection of Antiepileptic Drugs for the Treatment of Epilepsy in Children and Adults
The Selection of Antiepileptic Drugs for the Treatment of Epilepsy in Children and Adults Jorge J. Asconape, MD KEYWORDS Epilepsy Seizures Antiepileptic drugs Epilepsy is one of the most common chronic
More informationComplaints associated with the use of antiepileptic drugs: results from a community-based study
Seizure (2005) 14, 198 206 www.elsevier.com/locate/yseiz Complaints associated with the use of antiepileptic drugs: results from a community-based study J.A. Carpay a, *, A.P. Aldenkamp b, C.A. van Donselaar
More informationOpinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4
More informationChallenging epilepsy with antiepileptic pharmacotherapy in a tertiary teaching hospital in Sri Lanka
Original Article Challenging epilepsy with antiepileptic pharmacotherapy in a tertiary teaching hospital in Sri Lanka S. H. Kariyawasam, Namal Bandara,* A. Koralagama,** Sunethra Senanayake*** Dept. of
More information2 nd Line Treatments for Dravet. Eric BJ Ségal, MD Northeast Regional Epilepsy Group
2 nd Line Treatments for Dravet Eric BJ Ségal, MD Northeast Regional Epilepsy Group Disclosures Accepted honoraria from Greenwich Pharmaceuticals, Zogenix, Eisai, Lundbeck, Lineagen. Overview Evidence
More informationData from the World Health Organization suggest
CONTINUING PHARMACY EDUCATION Review of the Newer Antiepileptic Drugs Angel Tidwell, PharmD; and Melanie Swims, PharmD, BCPS AUDIENCE This activity is designed for pharmacists, pharmacy directors, managed
More informationSEIZURES PHARMACOLOGY. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
SEIZURES PHARMACOLOGY University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Understand the pharmacodynamics involved in the medications used to treat seizures
More informationTOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER)
divalproex sodium TOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER) Pharmacodynamics study of what a drug does to the body Divalproex sodium is chemically compounded from sodium valproate and
More informationInteractions between Antiepileptics and Second- Generation Antipsychotics
University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 3-2012 Interactions between Antiepileptics and Second- Generation Antipsychotics Jose de Leon University of Kentucky, jdeleon@uky.edu
More informationEfficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities
Seizure 004; : 68 75 doi:0.06/s059-(0)0054-7 Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities B. HUBER, W. BÖMMEL, I. HAUSER, V. HORSTMANN,
More informationAppendix M Health Economic Evidence Extractions
Appendix M Health Economic Evidence Extractions Which AEDs are clinically effective and cost-effective for people with focal epilepsy with or without secondary generalisation seizures? Frew E, Sandercock
More informationPharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers
Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers Effective: December 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationTHE TREATMENT GAP AND POSSIBLE THERAPIES OF EPILEPSY IN SUB- SAHARAN AFRICA
THE TREATMENT GAP AND POSSIBLE THERAPIES OF EPILEPSY IN SUB- SAHARAN AFRICA DR A.O. CHARWAY-FELLI, MD, PhD NEUROLOGIST 37 MILITARY HOSPITAL, ACCRA, GHANA SECRETARY-GENERAL AFRICAN ACADEMY OF NEUROLOGY
More informationOn completion of this chapter you should be able to: list the most common types of childhood epilepsies and their symptoms
9 Epilepsy The incidence of epilepsy is highest in the first two decades of life. It falls after that only to rise again in late life. Epilepsy is one of the most common chronic neurological condition
More informationEpilepsy: problems of diagnosis and recommended treatment Nicola Cooper MRCP and Morgan Feely MD, FRCP, FRCP(I)
Epilepsy: problems of diagnosis and recommended treatment Nicola Cooper MRCP and Morgan Feely MD, FRCP, FRCP(I) VM Our series Prescribing in gives practical advice for successful management of the special
More informationUnderstanding and Managing Epilepsy
Page 1 Understanding and Managing Epilepsy Jacquelyn L. Bainbridge, Pharm.D., FCCP Associate Professor University of Colorado Denver School of Pharmacy & Department of Neurology Supported by an educational
More informationDrug Monograph-Oxcarbazepine
Drug Monograph Generic name: Oxcarbazepine Brand name: Trileptal Manufacturer: Norvatis (www.norvatis.com) Classification: Anti-epileptic drug Similar agents: Carbamazepine Summary Oxcarbazepine is a new
More informationTopics. What are Prediction Factors? Seizure type Etiologies Frequency of seizures Response to first AED Genetic?
Early Recognition and Management of Refractory Epilepsy Topics How to predict who developed refractory epilepsy Associate Professor Somsak Tiamkao Division of Neurology, Department of Medicine Faculty
More information11b). Does the use of folic acid preconceptually decrease the risk of foetal malformations in women with epilepsy?
updated 2012 Management of epilepsy in women of child bearing age Q11: 11a). In women with epilepsy, should antiepileptic therapy be prescribed as monotherapy or polytherapy to decrease the risk of fetal
More informationAPPENDIX K Pharmacological Management
1 2 3 4 APPENDIX K Pharmacological Management Table 1 AED options by seizure type Table 1 AED options by seizure type Seizure type First-line AEDs Adjunctive AEDs Generalised tonic clonic Lamotrigine Oxcarbazepine
More informationeslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd
eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd 8 October 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationRefractory epilepsy: treatment with new antiepileptic drugs
Seizure 2000; 9: 51 57 doi: 10.1053/seiz.1999.0348, available online at http://www.idealibrary.com on Refractory epilepsy: treatment with new antiepileptic drugs P. K. DATTA & P. M. CRAWFORD Department
More informationDrug Choice in New-Onset Epilepsy December 6, 2013
Drug Choice in New-Onset Epilepsy December 6, 2013 Tracy A. Glauser, M.D. Director, Comprehensive Epilepsy Center Cincinnati Children s Hospital Medical Center American Epilepsy Society Annual Meeting
More informationThe following information is based partially
SELECTING APPROPRIATE PHARMACOTHERAPY FOR THE CHILD WITH EPILEPSY * Raman Sankar, MD, PhD ABSTRACT Selection of an antiepileptic drug (AED) for initial treatment of epilepsy in infancy, childhood, and
More informationRohit R. Das, 1 David A. Griesemer, 2 and Sanjeev V. Kothare Introduction. 2. Methods
ISRN Neurology Volume 2013, Article ID 613456, 4 pages http://dx.doi.org/10.1155/2013/613456 Research Article The Role of Phenytoin in the Treatment of Localization Related Epilepsy: An International Internet-Based
More informationSafety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials
Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials Ahmad Beydoun, M.D. Oxcarbazepine is approved as monotherapy and adjunctive therapy for partial seizures with and without
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationHow to choose/use anti-epileptic drugs wisely? Dr. Chusak Limotai, MD., M.Sc., CSCN(C)
How to choose/use anti-epileptic drugs wisely? Dr. Chusak Limotai, MD., M.Sc., CSCN(C) Talk overview When to start treatment? Which drug? Monotherapy Combining AEDs (Rational polytherapy) Old AEDs versus
More informationI. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs)
1 2 I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity
More informationAEDs in 2011: A Critical Comparative Review December 3, 2011
AEDs in 2011: A Critical Comparative Review December 3, 2011 Selim R. Benbadis, M.D. University of South Florida Tampa, FL American Epilepsy Society Annual Meeting Disclosure Speakers bureau Consultant
More informationManagement of Epilepsy in Pregnancy
Management of Epilepsy in Pregnancy September 7, 2018 Stephanie Paolini, MD Clinical Instructor/Women s Neurology Fellow UPMC Neurology We ve come a long way Sterilization of people with epilepsy was legal
More informationIn our patients the cause of seizures can be broadly divided into structural and systemic causes.
Guidelines for the management of Seizures Amalgamation and update of previous policies 7 (Seizure guidelines, ND, 2015) and 9 (Status epilepticus, KJ, 2011) Seizures can occur in up to 15% of the Palliative
More information